Butt Muhammad I, Albalwi Roaa M H, Alnassar Norah, Alghamdi Reem
Departments of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Department of Medicine, Al Faisal University, Riyadh, Saudi Arabia.
Sultan Qaboos Univ Med J. 2025 May 2;25(1):91-97. doi: 10.18295/squmj.10.2024.057. eCollection 2025.
Sodium-glucose transport protein 2 (SGLT2) inhibitors are used in the treatment of patients with type 2 diabetes. Besides their beneficial metabolic effects, such as lowering glycated haemoglobin, body weight and blood pressure, these agents have shown favourable and protective effects on both the heart and kidneys. Notably, these cardio-renal benefits are even seen in individuals without diabetes. However, there is limited evidence regarding the safety and efficacy of SGLT2 inhibitors in cardiac transplant recipients. This study aimed to assess the safety and efficacy of empagliflozin in cardiac transplant recipients with diabetes.
This retrospective study was conducted at the King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia, from June 2003 to May 2024. Patients from the cardiac transplant recipient register who were taking empagliflozin or a combination of empagliflozin and metformin were included. Consequently, their safety and efficacy parameters were examined.
A total of 20 patients were included in this study. There was an improvement in haemoglobin A1C (HbA1C) levels, body weight and stability in serum creatinine. Additionally, there was no increased risk of genitourinary infections, hypoglycaemia or diabetic ketoacidosis.
Although larger studies are needed to examine the use of empagliflozin in cardiac transplant patients, this small study provides assurance that empagliflozin is safe for use in cardiac transplant recipients.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂用于治疗2型糖尿病患者。除了具有有益的代谢作用，如降低糖化血红蛋白、体重和血压外，这些药物对心脏和肾脏均显示出有利和保护作用。值得注意的是，即使在无糖尿病个体中也能观察到这些心肾益处。然而，关于SGLT2抑制剂在心脏移植受者中的安全性和有效性的证据有限。本研究旨在评估恩格列净在糖尿病心脏移植受者中的安全性和有效性。
本回顾性研究于2003年6月至2024年5月在沙特阿拉伯利雅得的法赫德国王专科医院和研究中心进行。纳入心脏移植受者登记册中正在服用恩格列净或恩格列净与二甲双胍联合用药的患者。因此，对他们的安全性和有效性参数进行了检查。
本研究共纳入20例患者。糖化血红蛋白（HbA1C）水平、体重有所改善，血清肌酐保持稳定。此外，泌尿生殖系统感染、低血糖或糖尿病酮症酸中毒的风险没有增加。
尽管需要更大规模的研究来考察恩格列净在心脏移植患者中的应用，但这项小型研究证实了恩格列净在心脏移植受者中使用是安全的。
